The expression of AKT2 was significantly correlated with the progression free survival (PFS) (χ2=12.671, P=0.005) and the overall survival (OS) (χ2=9.851, P=0.021) of patients with NSCLC. Here, AKT2 is linked to non-small cell lung carcinoma.